ANI Pharmaceuticals (ANIP) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.

Does the media prefer AXSM or ANIP?

In the previous week, Axsome Therapeutics had 1 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 16 mentions for Axsome Therapeutics and 15 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.07 beat Axsome Therapeutics' score of 1.01 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in AXSM or ANIP?

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is AXSM or ANIP more profitable?

ANI Pharmaceuticals has a net margin of -1.28% compared to Axsome Therapeutics' net margin of -74.47%. ANI Pharmaceuticals' return on equity of 15.87% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-74.47%	-223.51%	-39.88%
ANI Pharmaceuticals	-1.28%	15.87%	6.88%

Does the MarketBeat Community prefer AXSM or ANIP?

Axsome Therapeutics received 43 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 70.76% of users gave Axsome Therapeutics an outperform vote while only 64.19% of users gave ANI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Axsome Therapeutics	Outperform Votes 484 70.76%	Underperform Votes 200 29.24%
ANI Pharmaceuticals	Outperform Votes 441 64.19%	Underperform Votes 246 35.81%

Which has better earnings & valuation, AXSM or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$432.16M	12.34	-$287.22M	-$5.77	-18.78
ANI Pharmaceuticals	$674.07M	1.96	$18.78M	-$1.27	-47.75

Do analysts recommend AXSM or ANIP?

Axsome Therapeutics currently has a consensus price target of $172.14, suggesting a potential upside of 58.88%. ANI Pharmaceuticals has a consensus price target of $80.13, suggesting a potential upside of 32.13%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk & volatility, AXSM or ANIP?

Axsome Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Summary

Axsome Therapeutics beats ANI Pharmaceuticals on 10 of the 18 factors compared between the two stocks.